1st Quarter - Report

SANOFI PASTEUR, INC. (FORMERLY AVENTIS PASTEUR) for SANOFI PASTEUR INC (FORMERLY AVENTIS PASTEUR)

Firm
Client
Income
—
Expenses
$440,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Legislation and other issues involving vaccine taxes and children's health, vaccine-related issues with respect to Medicaid and Medicare, and vaccine-related general tax issues.

Foreign entity interest: Sanofi Aventis Group has an interest in this legislation due to the potential impact on their U.S. business.

LobbyistCovered position, as disclosed
SEAN CALLINICOS —
STUART FELDMAN New —
AMY L REDL —

Contacted: Health & Human Services, Dept of (HHS); Homeland Security, Dept of (DHS); Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Patent Reform Issues

Foreign entity interest: Sanofi Aventis Group has an interest in this legislation due to the potential impact on their U.S. business.

LobbyistCovered position, as disclosed
SEAN CALLINICOS —
STUART FELDMAN New —
AMY L REDL —

Contacted: HOUSE OF REPRESENTATIVES; Homeland Security, Dept of (DHS); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); SENATE

Trade (domestic/foreign) TRD

Vaccine-related legislation, advance market commitments, and other issues.

Foreign entity interest: Sanofi Aventis Group has an interest in this legislation due to the potential impact on their U.S. business.

LobbyistCovered position, as disclosed
SEAN CALLINICOS —
STUART FELDMAN New —
AMY L REDL —

Contacted: HOUSE OF REPRESENTATIVES; Homeland Security, Dept of (DHS); Health & Human Services, Dept of (HHS); SENATE; Executive Office of the President (EOP)

Health Issues HCR

All vaccine and generic biological issues and related appropriation issues, including vaccines for children, pandemic concerns, influenza vaccine shortage issues, stockpile, bioterrorism, bioterrorism countermeasures, vaccine injury compensation programs, vaccine safety funding and financing, and FDA and CDC funding.

Foreign entity interest: Sanofi Aventis Group has an interest in this legislation due to the potential impact on their U.S. business.

LobbyistCovered position, as disclosed
SEAN CALLINICOS —
STUART FELDMAN New —
AMY L REDL —

Contacted: Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES; Homeland Security, Dept of (DHS); Health & Human Services, Dept of (HHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.